Determination of the Diagnostic Values of Asymmetric Dimethylarginine as an Indicator for Evaluation of the Endothelial Dysfunction in Patients with Rheumatoid Arthritis

Table 2

Distribution of ADMA, reactant of acute phase and other laboratory variables in patients with RA and healthy control group.

	Ra not treated group; no. 35; Value (M ± SD)	RA^sero−; no. 18; Value (M ± SD)	RA^sero+; no. 17; Value (M ± SD)	Control healthy group; no. 35; Value (M ± SD)
	Positive/negative	Positive/negative	Positive/negative	Positive/negative
ADMA; +>0.75 μmol/L	20/15; 08.10 (±0.75); (0–210)	7/11; 11.22 (±0.72); (0–110)	13/4; 13.16 (±0.40); (0–210)	4/31; 11.75 (±0.22); (55.20–105.33)
Sedimentation; +≥16	25/10; 46.43 (±41.79); (1.0–110)	11/7; 40.70 (±37.63); (1.0–110)	13/4; 51.38 (±37.37); (1.0–110)	3/32; 7.31 (±7.10); (1.0–31)
Anti CCP2; ≥1.26	24/11; 1.82 (±0.71); (0.91–2.0)	12/6; 1.45 (±0.48); (0.91–1.5)	11/6; 1.76 (±0.80); (0.91–1.9)	1/34; 0.84 (±0.09); (0.90–1.27)
RF; +≥8 IU/mL	18/17; 335.09 (±515.11); (0.00–512)	0/18; 0.00 (±0.00); (0.00-0.00)	17/0; 601.67 (±622.68); (32–1024)	3/32; 11.69 (±40.69); (0.00–128)
DAS28; +≥3.2	29/6; 5.81 (±1.44); (1.76–6.01)	14/4; 5.30 (±1.55); (1.72–6.01)	16/1; 4.01 (±1.29); (1.39–5.81)	0/35; 0.00 (±0.00); (0.00-0.00)